Introduction
Intravesical bacille Calmette-Gu erin (BCG) has been used as treatment for intermediate-and high-risk non-muscleinvasive bladder cancer (NMIBC). In recent practice, there have been two primary companies licensed in the USA that manufactured an attenuated live culture preparation of BCG for the treatment of NMIBC. Such products included: TICE In April 2012, the USA Food and Drug Administration (FDA) determined that Sanofi Pasteur was not suitable to produce BCG due to limitations in manufacture and sterility of the TheraCys BCG live intravesical product [1] . These breaches led to Sanofi Pasteur Ltd closing their manufacturing plant and suspended manufacturing of TheraCys in Toronto, Ontario, Canada on 21 June, 2012. Following this, TICE demands exceeded the available inventory of the product. In October 2014, Health Canada reinstated Sanofi Pasteur Ltd with a Drug Establishment License for manufacturing BCG products in its Toronto facility. Accordingly, the treatment algorithm for NMIBC has been effected considerably with alternate treatment options being recommended [2] . We aimed to determine prescription patterns over the past decade for BCG in Australia during the global shortage and subsequent resumption of availability.
Methods
Between April 2006 and April 2016, monthly data for BCG prescriptions were extracted from the Pharmaceutical Benefits Australia website [3] . The following codes were used: Pharmaceutical Benefit Schedule codes 1140B and 5901N (carcinoma in situ [CIS] of urinary bladder), 1131M (primary urothelial carcinoma of the bladder) and 5902P (relapsing superficial urothelial carcinoma of the bladder). The numbers of prescriptions for each indication per month were plotted on a stacked area graph. Between any identified breakpoints, linear regression was used to estimate the monthly rate of change of prescriptions issued. Periodicity was assessed by inspection of a log-standardised periodogram of the raw values and month-to-month change values for each indication, as well as the total. Evidence against the hypothesis that any series has a unit root was evaluated with the Phillips-Perron test including a trend term [4] with 0.05 taken as a significant value. Strong evidence against this hypothesis indicates that a series exhibits stationary behaviour. Analysis was performed using Stata version 12.0SE (College Station, TX, USA).
Results
The average annual incidence of Bladder Cancer (all types) in Australia over the study period was 2 325. The total monthly BCG prescriptions in the study period ranged from 178 in second interval, the mean number of uses averaged 75 per month, whilst in the third interval the average fell to 6.4 per month (Fig. 1b) . The monthly growth in uses for primary or relapsing TCC was slow in interval one (Table 1) . In subsequent intervals, the growth in prescriptions for both indications rose markedly with a 22.8 per month average increase in uses for primary TCC in interval three and the peak month for use occurring in the last month of the study period. BCG use for relapsing TCC also grew at 3.79 per month following the second breakpoint in contrast to prescriptions for CIS, which have not shown any monthly growth in interval three from a low base.
Inspection of log-standardised periodograms for all series showed no obvious periodicity. There was strong evidence against the hypothesis that the series of prescriptions for primary and relapsing TCC contained a unit root (P < 0.001). That is, they are likely to be stationary series and thus revert to a previous trend or mean following external shocks. There was a lack of evidence that the series for CIS did not contain a unit root (P = 0.12) and hence shocks have a permanent effect on the mean of the series.
Discussion
After restoration of the global shortage of BCG, Australian prescription patterns for BCG are conflicting with contemporary international guidelines that form the standard of care for the nation's practice. Specifically, prescription patterns show that prescriptions for CIS are lacking, whilst for primary and recurrent TCC has resumed as previous. Other treatment options in Australia during this period included: intravesical mitomycin, doxorubicin (adriamycin), and gemcitabine. Device-assisted therapy was only in use in two trial centres during the study period and not freely available.
Multiple organisational guidelines exist pertaining to the role of intravesical BCG therapy in the treatment of NMIBC. At the time of the shortage, the European Association of Urology (EAU) released a press release suggested continuing BCG therapy or replacing with intravesical chemotherapeutic agents for up to 12 months [5] . Similarly, Veeratterapillay et al. [2] published recommendations during the BCG shortage, suggesting either: one-third dose BCG for induction and maintenance for 1 year, induction and maintenance with mitomycin C or gemcitabine, intravesical chemotherapy with thermotherapy or primary radical cystectomy. Despite these recommendations during the shortage, the resumption of production and improved availability of BCG would have intuitively resulted in the increased prescription of BCG for CIS. From the present data, we are unable to discern the precise causation in the alteration in this practice pattern, but no doubt warrants further in depth review.
There are several limitations to the present study. Firstly, there are inherent limitations with the use of Medicare Benefits Schedule (MBS)-based billing data, as data are dependent on the accurate billing by clinicians. Despite these concerns, Pharmaceutical Benefit Schedule-based data has been validated for use in the setting of alternate surgical procedures [6] . Due to removal of items from the Pharmaceutical Benefit Schedule during the study period, data pertaining to alternative intravesical agents including mitomycin C, doxorubicin (adriamycin) or gemcitabine were not available for analysis. Further, granular BCG data related to disease characteristics and prescriber demographics were not available for analysis.
In conclusion, after resumption of normal production of BCG following the recent global shortage, MBS data suggests prescription patterns for CIS are deficient. Such prescription patterns for CIS are conflicting with international guidelines reporting management strategies for NMIBC. There is a critical need for improved management of CIS in the current state of BCG availability. Developments in assisted reproductive techniques (ART) have transformed the management of male factor infertility and the advent of intracytoplasmic sperm injection (ICSI) in 1993 was a landmark in the management of the infertile male. While this has been an undoubted success, it has led to a shift away from understanding and correcting the potential reversible causes of male factor infertility, to one that simply overcomes it with ART.
The aetiology of male infertility can broadly be divided into impaired spermatogenesis, or impaired sperm transport within the genital tract. The most challenging of these is male infertility attributable to azoospermia, which affects approximately 10-15% of infertile men (2.7 million men in Europe).
In recent years, the investigation and treatment of men in the UK presenting with infertility has been variable, depending on the patient's geographical location and access to male fertility specialists. In April 2017 NHS England (NHSE) published a commissioning policy (B14X07/01) relating to surgical sperm retrieval (SSR) for infertile men. In this document it is proposed that commissioning for SSR should be limited to men '..diagnosed with azoospermia by a urologist with an interest in male infertility problems in a specialized urology centre with established links with an HFEA [Human Fertilisation and Embryology Authority]-licensed fertility centre' or men who are due to undergo '. . .surgery or chemotherapy that would result in infertility, and who cannot produce sufficient sperm for storage'. Cases commissioned for SSR must have '..a reasonable likelihood of successful retrieval of motile sperm' and 'confirmed funding for subsequent stages of the pathway (cryopreservation and/or IVF treatment)' [2] . Whilst the document focuses on patients requiring SSR, it is important to remember that there are potential reversible causes for azoospermia, which are often overlooked. These should be investigated at the outset and patients informed of the potential medical or surgical interventions available and the likely outcomes with regard to live birth rates. The aim is to try and restore natural fertility wherever possible, rather than to resort to ART as a first-line treatment option.
